New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 27, 2013
15:21 EDTANW, PLL, MYL, MNST, LTD, JCP, GRPN, BOOM, CSGP, WESCompanies reporting After the Market Close on Wednesday, February 27
Notable companies reporting after the closing bell on Wednesday include Aegean Marine Petroleum Network (ANW), CoStar Group (CSGP), Dynamic Materials (BOOM), Groupon (GRPN), J C Penney (JCP), Limited Brands (LTD), Monster Beverage (MNST), Mylan (MYL), Pall (PLL), and Western Gas Partners (WES).
News For ANW;CSGP;BOOM;GRPN;JCP;LTD;MNST;MYL;PLL;WES From The Last 14 Days
Check below for free stories on ANW;CSGP;BOOM;GRPN;JCP;LTD;MNST;MYL;PLL;WES the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
April 22, 2014
05:47 EDTJCPStocks with implied volatility movement; JCP CRM
Subscribe for More Information
April 21, 2014
08:18 EDTMYLMomenta Pharma rises after high court rejects Copaxone delay bid
Shares of Momenta Pharmaceuticals (MNTA) are higher in pre-market trading after the Supreme Court denied Teva's (TEVA) request to delay the launch of generic forms of its relapsing-remitting multiple sclerosis product, Copaxone. WHAT'S NEW: Teva confirmed on April 19 that the Chief Justice of the United States denied the company's application for an injunction seeking to prevent the launch of a generic version of Copaxone. Teva will continue pursuing its appeal in the Supreme Court and defending its intellectual property for Copaxone, the company said. WHAT'S NOTABLE: Momenta has developed a generic version of Copaxone in partnership with Novartis' (NVS) Sandoz unit. Mylan, which is preparing to launch a generic version of Copaxone as well, said after the ruling: "We are pleased with the Chief Justice's decision, and we look forward to introducing the first generic Copaxone treatment for multiple sclerosis patients in the U.S. at market formation. Mylan remains eligible to receive approval from the U.S. FDA on May 25, 2014." PRICE ACTION: In pre-market trading, Momenta shares are up over 12% to $12.46, while Mylan shares are up more than 3% to $48.48. Teva shares trading in New York are down about 1.7% to $50 in pre-market trading.
08:06 EDTMNSTMonster Beverage agrees to settle class action suit over Anheuser-Busch pact
Subscribe for More Information
07:00 EDTCSGPCoStar Group pullback a buying opportunity, says William Blair
William Blair views the recent pullback in shares of CoStar Group as a buying opportunity. The firm expects CoStar to report solid results on Wednesday and it keeps an Outperform rating on the stock.
06:26 EDTCSGPCoStar Group upgraded to Buy from Neutral at B. Riley
Subscribe for More Information
April 19, 2014
18:50 EDTMYLMylan says Teva denied injunction seeking to prevent launch of generic Copaxone
Subscribe for More Information
April 17, 2014
04:22 EDTMYLMylan (MYL) implied volatility of 45 at upper end of index mean range
April 16, 2014
16:16 EDTMYLMylan launches first generic Ortho Evra patch
Subscribe for More Information
April 15, 2014
10:21 EDTMYLMylan announces settlement agreement for first-to-file Generess
Subscribe for More Information
10:10 EDTMYLMylan launches generic Lunesta tablets
Subscribe for More Information
08:07 EDTMYLActavis announces agreement related to Generess FE patent challenge litigation
Actavis (ACT) announced that it has entered into an agreement with Mylan (MYL) and Famy Care to settle all outstanding patent litigation related to Mylan's generic version of Generess. Under the terms of the agreement, Actavis will grant Mylan a license to market its generic version of Generess® FE under its pending Abbreviated New Drug Application beginning on April 1, 2015. Alternatively, Mylan will be permitted to launch an authorized generic version of Actavis' product beginning on October 1, 2015. Other terms of the settlement were not disclosed. Actavis remains in litigation with Lupin Ltd in connection with Lupin's pending ANDA for a generic version of Generess.
08:06 EDTMYLProsonix, Mylan enter licensing deal for generic version of Flixotide, Flovent
Subscribe for More Information
April 14, 2014
08:53 EDTGRPNGroupon May volatility elevated at 74 into Q1 and outlook
Subscribe for More Information
April 11, 2014
14:26 EDTJCPCBL & Associates expects more J.C. Penney closures
Subscribe for More Information
11:50 EDTMYLStocks with call strike movement; TNA MYL
Subscribe for More Information
10:56 EDTGRPNOptions with increasing implied volatility: CYTK VJET DATA GRPN CTRP
10:30 EDTMYLActavis and Mylan shares recommended at Bernstein
07:31 EDTMYLMylan confirms judge enforces agreement with Endo regarding generic Frova
Subscribe for More Information
April 10, 2014
09:34 EDTGRPNGroupon adds in-store coupons to Freebies category
Subscribe for More Information
08:59 EDTMNSTMonster Beverage May volatility elevated at 38
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use